Gyre Therapeutics Inc GYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.11
- Day Range
- $7.09–7.43
- 52-Week Range
- $5.44–9.42
- Bid/Ask
- $6.88 / $7.74
- Shares Outstanding
- 106.03M
- Market Cap
- $779.35M
- Volume/Avg
- 181,458 / 104,604
Key Statistics
- Price/Earnings (Normalized)
- 565.23
- Price/Sales
- 6.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 618
- Website
- https://www.gyretx.com
Valuation
|
Metric
|
GYRE
|
|---|---|
Price/Earnings (Normalized) | 565.23 |
Price/Book Value | 6.99 |
Price/Sales | 6.30 |
Price/Cash Flow | — |
Price/Earnings
GYRE
Financial Strength
|
Metric
|
GYRE
|
|---|---|
Quick Ratio | 3.59 |
Current Ratio | 4.26 |
Interest Coverage | — |
Quick Ratio
GYRE
Profitability
|
Metric
|
GYRE
|
|---|---|
Return on Assets (Normalized) | −4.80% |
Return on Equity (Normalized) | −7.91% |
Return on Invested Capital (Normalized) | −5.78% |
Return on Assets
GYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|v>%DPnm | LOCK|<R%^ | $128B | |||
| Moderna Inc
MRNA
| LOCK|rwTklG | LOCK|^c | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Rk<?^s | LOCK|!j<d | $75B | |||
| argenx SE ADR
ARGX
| LOCK|THX?M> | LOCK|ty | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>!Q%FV | LOCK|&> | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&nYsgNf | LOCK|<lM% | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?P?tdy< | LOCK|^?mF | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$jH&@t | LOCK|?H# | $25B | |||
| Incyte Corp
INCY
| LOCK|<Cq&?# | LOCK|hP | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%!b>pqg | LOCK|^X | $15B |
United States